[Evaluation of the second line of treatment of patients with small cell carcinoma of the lung].
Efficacy of second line therapy which included vepesid and adriamycin or vepesid, adriamycin and cis-platin, in small cell lung cancer was studied. Objective remission was seen in 35% of the once more treated patients. Analysis of survival time showed significant prolongation of it in cases treated once more in comparison with a group of patients with progression of the neoplastic process during primary therapy or patients not treated due to relapses of the process. The observed difference was bigger in patients that reacted with a remission to the second line therapy.
Roszkowski
K
K
Janic
G
G
Jassem
J
J
Karnicka-Młodkowska
H
H
Szczepek
B
B
Traczyk
K
K
Zych
J
J
Rowińska-Zakrzewska
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D012074:Remission Induction
D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin
Ocena skuteczności drugiego rzutu leczenia chorych na drobnokomórkowego raka płuca.